BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10747832)

  • 1. Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
    Ednie LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2000 Apr; 45(4):525-8. PubMed ID: 10747832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
    Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):195-201. PubMed ID: 10904193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
    Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
    Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
    Kelly LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):707-9. PubMed ID: 10382894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
    Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
    Jones RN; Barrett MS; Deguchi T
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):323-6. PubMed ID: 12151195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
    Calvo A; Giménez MJ; Alou L; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2002 Aug; 20(2):144-6. PubMed ID: 12297365
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.